CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine headaches in adults. The Company is developing intravenous lasmiditan for the acute treatment of unspecified non-traumatic primary headache in adults in emergency room and other urgent care settings, and other unmet medical needs. Lasmiditan is designed to treat migraine using a mechanism by acting as an agonist at the fifth human serotonin receptor. Lasmiditan is designed to penetrate the central nervous system and to block the pathway that contributes to headache.
